首页> 外文期刊>European journal of clinical microbiology and infectious diseases: Official publication of the European Society of Clinical Microbiology >Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.
【24h】

Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward.

机译:成人血液肿瘤科病房中难辨梭状芽孢杆菌相关性腹泻的危险因素。

获取原文
获取原文并翻译 | 示例
           

摘要

Nosocomial diarrhea caused by Clostridium difficile causes significant morbidity and mortality in an increasing proportion of hospitalized patients annually. This case-control study of patients admitted to the hematology-oncology ward of a tertiary academic medical center over a 2-year period demonstrates that patients with Clostridium difficile-associated diarrhea (CDAD) were 22 times more likely than ward-matched controls with diarrhea to have received any antibiotic either during hospitalization or in the month preceding admission (p < 0.005), and they were nearly three times as likely as controls to have received a cephalosporin during the same period (p < 0.005). Diarrhea among lung cancer patients was approximately three times more likely to be caused by this organism than to be due to other causes (p = 0.04). A trend towards CDAD patients receiving higher numbers of different antibiotics during hospitalization (3.3 vs. 2.6, 95%CI -1.42-0.02, p = 0.06) was noted. Administration of interleukin-2 either during hospitalization or in the 30 days preceding admission was seven times more likely to have occurred in CDAD cases (p = 0.04), raising the question of whether or not this agent increases risk.
机译:艰难梭状芽胞杆菌引起的院内腹泻每年在住院患者中所占的比例越来越高,从而导致明显的发病率和死亡率。这项为期两年的对三级学术医学中心血液肿瘤病房住院患者的病例对照研究表明,艰难梭菌相关性腹泻(CDAD)患者的病情比病原匹配的腹泻患者高22倍在住院期间或入院前一个月中已接受任何抗生素治疗(p <0.005),并且在同一时期内接受头孢菌素治疗的可能性是对照组的近三倍(p <0.005)。肺癌患者腹泻的可能性是这种微生物引起的腹泻的可能性是其他原因引起的腹泻的可能性的三倍(p = 0.04)。注意到CDAD患者住院期间接受更多不同抗生素的趋势(3.3 vs. 2.6,95%CI -1.42-0.02,p = 0.06)。在CDAD病例中,住院期间或入院前30天服用白细胞介素2的可能性要高出7倍(p = 0.04),这增加了该药物是否增加风险的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号